Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Equity Ratio: 2010-2025

Historic Equity Ratio for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to 0.78.

  • Iovance Biotherapeutics' Equity Ratio was N/A to 0.78 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.78, marking a year-over-year change of. This contributed to the annual value of 0.78 for FY2024, which is 4.16% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Equity Ratio stood at 0.78 for Q3 2025, which was up 0.82% from 0.77 recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Equity Ratio ranged from a high of 0.81 in Q1 2023 and a low of 0.75 during Q4 2023.
  • Moreover, its 3-year median value for Equity Ratio was 0.78 (2024), whereas its average is 0.78.
  • Over the last 5 years, Iovance Biotherapeutics' Equity Ratio had its largest YoY gain of 4.16% in 2024, and its largest YoY loss of 3.31% in 2024.
  • Over the past 3 years, Iovance Biotherapeutics' Equity Ratio (Quarterly) stood at 0.75 in 2023, then climbed by 4.16% to 0.78 in 2024, then grew by 1.60% to 0.78 in 2025.
  • Its Equity Ratio stands at 0.78 for Q3 2025, versus 0.77 for Q2 2025 and 0.79 for Q1 2025.